OPN-a splicing variant expression in non-small cell lung cancer and its effects on the bone Metastatic abilities of lung cancer cells in vitro

15Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Background: Osteopontin (OPN) is known to be involved in the development of certain cancers, including non-small cell lung cancer (NSCLC). However, its role in tumour progression remains unclear. The present study investigated the expression and biological impact of the OPN variant, OPN-a in NSCLC. Materials and Methods: OPN-a splicing variant expression in human NSCLC tissues was analyzed by real-time qPCR and immunohistochemistry (IHC), respectively. The impact of OPN-a on cellular functions of lung cancer cells was also evaluated. In addition, an in vitro model was developed for the assessment of interactions between lung cancer cells and bone tissue. Results: The expression of OPN-a was higher in lung cancer tissues compared to normal controls. OPN-a promoted the malignant phenotypes of A549 cells by enhancing celladherent abilities to bone tissues, which could be mediated by the interaction with the cell surface receptor αvβ3 integrin. Conclusion: OPN-a may represent a bone metastatic factor in human lung cancer, as well as a potential therapy target.

Cite

CITATION STYLE

APA

Hao, C., Cui, Y., Hu, M., Zhi, X., Zhang, L., Li, W., … Jiang, W. G. (2017). OPN-a splicing variant expression in non-small cell lung cancer and its effects on the bone Metastatic abilities of lung cancer cells in vitro. Anticancer Research, 37(5), 2245–2254. https://doi.org/10.21873/anticanres.11561

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free